InvestSMART

Botanix Pharmaceuticals Ltd (ASX:BOT)

ALERT: Price-sensitive ASX Announcement for BOT
Current share price for BOT : $0.020 -0.003 (-13.04%)+
Announcement
Release
27 Jul 2026 9:12AM
Price at Release
$0.023
Full Release
download
Summary
Botanix Pharmaceuticals Ltd reported significant developments in its Quarterly Activities Report and Appendix 4C for Q4 FY26. The company has strategically managed its financial position by deferring a $9.7 million API purchase, reducing manufacturing and operating costs, and completing a $45 million capital raise. Botanix is focused on sustainable growth through resource allocation, commercial execution, and cash flow optimization. The company is also expanding its gross margins and supply chain resilience by onboarding an alternative API supplier. Notably, Botanix has received a European patent grant and a US patent allowance, strengthening its intellectual property estate. The financial highlights include a cash balance increase to $36.6 million, a 12% reduction in sales force size to enhance operating efficiency, and the issuance of shares from exercised performance rights. The newly appointed Chief Operating Officer, Paul Seaback, will oversee operations to support growth and operational efficiencies.
Key Points
  • Manufacturing costs decreased to $1.2 million in Q4 FY26.
  • Operating costs reduced by 10% to $11.5 million.
  • Cash position increased to $36.6 million.
  • Successful $45 million capital raise completed.
  • Sales force realigned, reducing overall size by 12%.
  • Alternative API supplier onboarded for supply chain strength.
  • European patent grant and US patent allowance received.
  • Chief Operating Officer appointed to enhance operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.